Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Centre for Probe Development and Commercialization - CPDC

$28.8 million for 2008-18
About   |   News   |   Features   |   Videos
Centre for Probe Development and Commercialization

Number of partners
36

Partner contributions
$39 million

Headquarters
Hamilton, Ontario

CEO
John Valliant John Valliant

Board chair
Bob Sutherland Bob Sutherland
Senior Investment Officer, Ontario Institute for Cancer Research

Exploiting the power of molecular imaging to improve health care


The opportunity

With Canadians living longer, our health care system is struggling to cope with the diseases of an aging population. Molecular imaging is a powerful new technology that dramatically improves the way diseases are diagnosed and staged by injecting molecules (“probes”) that seek out disease sites and then send a signal to a camera. The technique provides information about where the disease is and its biochemical makeup. This makes it possible for doctors to diagnose disease at an earlier stage and select the best therapy for each individual patient. Scientists in the field of molecular imaging face barriers to make their discoveries accessible to health care providers and global markets. Their ground breaking innovations remain locked in research labs.

How CPDC is seizing the opportunity

The Centre for Probe Development and Commercialization (CPDC) works collaboratively with industry and academic partners to provide the expertise and infrastructure needed to develop and manufacture molecular imaging probes. An important part of Canada’s health system, CPDC provides a reliable, daily supply of imaging probes to hospitals and leading research teams. CPDC’s areas of expertise include pre-clinical development of new probes, regulatory affairs, Good Manufacturing Practices (GMP), and maintaining the systems and infrastructure needed to achieve Health Canada approval for clinical trials and the commercialization of innovative new products.

Among the results

  • CPDC, TRIUMF, Advanced Applied Physics Solutions, the BC Cancer Agency and the Lawson Health Institute found a way to adapt existing cyclotrons in Canadian hospitals to produce Tc-99m, a medical isotope used in imaging that is critical to Canada’s health care system.
  • CPDC launched a multi-centre Phase 1 clinical trial investigating the safety, whole body distribution and tumour uptake of a novel probe, which has potential as a diagnostic imaging agent and as a therapeutic radiopharmaceutical to treat a range of solid tumour types (e.g. lung, pancreas, breast, prostate).
  • CPDC increased the number of molecular imaging probe manufacturing sites, with locations now in Ottawa, Toronto and Hamilton, allowing the centre to supply more than 25,000 doses for patients in Canada.
  • In 2016, CPDC spun-off its second major company, Fusion Pharmaceuticals Inc., a new Canadian drug company developing therapeutics for the treatment of chemotherapy resistant cancers.

Connect with CPDC

 

Features
NCE community members among winners of prestigious Canadian science awards
February 18, 2015
The winners of prestigious science prizes given out to some of Canada’s top researchers include innovators who have made important contributions to NCE-funded networks and centres. The annual awards from the Natural Sciences and Engineering Research Council (NSERC) are bestowed for a wide range of world-class achievements by Canadian researchers that boost discovery, training and innovation in Canada. His Excellency the Right Honourable David Johnston, Governor General of Canada, honoured the winners at a ceremony at Rideau Hall on February 17. Read more
Centres of Excellence for Commercialization and Research Partnering with TRIUMF to Deliver Solutions to Medical Isotope Shortage
February 22, 2012
The Centre for Probe Development and Commercialization (CPDC) and Advanced Applied Physics Solutions (AAPS) are partnering with TRIUMF to deliver solutions to the medical isotope shortage. Read more
Videos
Watch Video
Centre for Probe Development and Commercialization (CPDC)
February 29, 2012